Rhythm Biosciences reports half-year financial results
Key points
- ColoSTAT® product moves from development to commercialisation
- geneType™ platform expands with new partnerships and scientific validation
- Successful $3.75 million capital raise strengthens balance sheet
Full summary
Rhythm Biosciences Limited reported a loss of $2.26 million for the half-year ended 31 December 2025, reflecting continued investment in commercialisation activities across both the ColoSTAT® and geneType™ platforms. The period marked a pivotal transition for ColoSTAT®, with the product moving from development into active commercialisation following the securing of ISO 15189:2022 laboratory accreditation. The geneType™ genetic risk assessment platform also demonstrated strong commercial and scientific momentum, with two strategic distribution partnerships secured and a collaboration with Memorial Sloan Kettering Cancer Center. The company successfully completed a $3.75 million capital raising, strengthening its balance sheet as it enters its commercial phase.
Summary generated by a large language model. Please interpret with care.